Affordable Access

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.

Authors
  • Therasse, P
  • Mauriac, L
  • Welnicka-Jaskiewicz, M
  • Bruning, P
  • Cufer, T
  • Bonnefoi, H
  • Tomiak, E
  • Pritchard, K I
  • Hamilton, A
  • Piccart, M J
Type
Published Article
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Date
Mar 01, 2003
Volume
21
Issue
5
Pages
843–850
Identifiers
PMID: 12610183
Source
Medline
License
Unknown

Abstract

Dose-intensified EC does not provide a measurable therapeutic benefit over CEF as neoadjuvant chemotherapy for unselected locally advanced breast cancer patients.

Report this publication

Statistics

Seen <100 times